MIPS # PIMSH 13 Mutation Testing for Stage IV Lung Cancer Completed Prior to the Start of Targeted Therapy

MEASURE DESCRIPTION

Proportion of stage IV nsNSCLC patients tested for actionable biomarkers and received targeted therapy or chemotherapy based on biomarker results.

Relevance to Value Based Care

Recent discovery of some of the driver mutations for NSCLC have advanced more individualized and targeted treatment options. It is now a standard recommendation that patients with advanced NSCLC undergo routine molecular testing to identify certain abnormalities which influence treatment selection to improve efficacy.

 Numerator

Patients who received mutation testing for all actionable biomarkers at Stage IV diagnosis of nsNSCLC (including NTRK1/2/3, RET, MET, ROS1, EGFR, EGFR T790M, BRAF mutation, ALK rearrangement, CD274(PD-L1), KRAS, ERBB2 mutation) AND lung cancer treated with appropriate mutation-directed therapy or standard chemotherapy if biomarker results are negative.

 Denominator

Patients with stage IV non-squamous, NSCLC receiving initial treatment during the measurement period AND patient encounter during the performance period.

 Exclusion/Exceptions

Lack of tissue for testing OR insufficient test results

 Scoring

5-point floor

 RESOURCES